JP2017517506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017517506A5 JP2017517506A5 JP2016568497A JP2016568497A JP2017517506A5 JP 2017517506 A5 JP2017517506 A5 JP 2017517506A5 JP 2016568497 A JP2016568497 A JP 2016568497A JP 2016568497 A JP2016568497 A JP 2016568497A JP 2017517506 A5 JP2017517506 A5 JP 2017517506A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- heavy chain
- light chain
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462001534P | 2014-05-21 | 2014-05-21 | |
| US62/001,534 | 2014-05-21 | ||
| PCT/US2015/031081 WO2015179236A1 (en) | 2014-05-21 | 2015-05-15 | Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017517506A JP2017517506A (ja) | 2017-06-29 |
| JP2017517506A5 true JP2017517506A5 (enExample) | 2018-07-12 |
Family
ID=53284562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568497A Pending JP2017517506A (ja) | 2014-05-21 | 2015-05-15 | 癌を処置するための抗ｃｃｒ４抗体および４−１ｂｂアゴニストの併用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10023649B2 (enExample) |
| EP (1) | EP3145956A1 (enExample) |
| JP (1) | JP2017517506A (enExample) |
| KR (1) | KR20170004006A (enExample) |
| CN (1) | CN106413751A (enExample) |
| AU (1) | AU2015264528A1 (enExample) |
| BR (1) | BR112016026993A2 (enExample) |
| CA (1) | CA2949214A1 (enExample) |
| IL (1) | IL248540A0 (enExample) |
| MX (1) | MX2016015181A (enExample) |
| RU (1) | RU2016146993A (enExample) |
| WO (1) | WO2015179236A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11213583B2 (en) * | 2014-02-05 | 2022-01-04 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| WO2017130076A1 (en) * | 2016-01-25 | 2017-08-03 | Pfizer Inc. | Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US10780080B2 (en) * | 2016-11-23 | 2020-09-22 | Translational Drug Development, Llc | Benzamide and active compound compositions and methods of use |
| US10174122B2 (en) | 2017-01-06 | 2019-01-08 | Eutilex Co., Ltd. | Anti-human 4-1BB antibodies and uses thereof |
| PT3431105T (pt) * | 2017-03-29 | 2020-03-11 | Shionogi & Co | Composição medicinal para tratamento de cancro |
| ES3000510T3 (en) | 2017-06-09 | 2025-02-28 | Providence Health & Services Oregon | Tumor-infiltrating t-cells for use in the treatment of cancer |
| SG10201913147WA (en) | 2017-07-11 | 2020-02-27 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
| KR20250020679A (ko) | 2017-08-04 | 2025-02-11 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
| WO2019072274A1 (zh) * | 2017-10-12 | 2019-04-18 | 瑞阳(苏州)生物科技有限公司 | 一种激动型4-1bb单克隆抗体 |
| CN109651507B (zh) | 2017-10-12 | 2021-11-26 | 瑞阳(苏州)生物科技有限公司 | 一种激动型4-1bb单克隆抗体 |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| AU2018360766B2 (en) | 2017-11-06 | 2024-09-19 | Rapt Therapeutics, Inc. | Anticancer agents |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2019109238A1 (en) * | 2017-12-05 | 2019-06-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 antibodies and uses thereof |
| TW201932491A (zh) * | 2018-01-22 | 2019-08-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗４－１ｂｂ抗體、其抗原結合片段及其醫藥用途 |
| PL3765489T3 (pl) * | 2018-03-13 | 2025-02-10 | F. Hoffmann-La Roche Ag | Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20 |
| WO2019196868A1 (en) * | 2018-04-10 | 2019-10-17 | Wuxi Biologics (Shanghai) Co., Ltd. | A monoclonal antibody against human 4-1bb, method for preparing the same, and use thereof |
| WO2019241730A2 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| JP7598312B2 (ja) | 2018-07-23 | 2024-12-11 | ハイデルベルク ファーマ リサーチ ゲーエムベーハー | 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用 |
| WO2020216947A1 (en) | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| CA3139274A1 (en) | 2019-05-10 | 2020-11-19 | Lyvgen Biopharma Co., Ltd. | Humanized anti-cd137 antibodies and uses thereof |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| KR20220127859A (ko) * | 2020-01-13 | 2022-09-20 | 사이토딘 인크. | Ccr5 양성 전이성 암 치료를 위한 ccr5 결합제 |
| WO2021156326A1 (en) * | 2020-02-04 | 2021-08-12 | Genmab A/S | Antibodies for use in therapy |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
| AU2021362156A1 (en) * | 2020-10-13 | 2023-06-15 | Board Of Regents, The University Of Texas System | Combinatorial immunotherapeutic methods and compositions for pancreatic ductal adenocarcinoma treatment |
| CN116916952A (zh) * | 2020-12-04 | 2023-10-20 | 宏观基因有限公司 | HER2/neu抗体的药物组合物及其用途 |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| US20240277842A1 (en) | 2021-06-07 | 2024-08-22 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
| US20240316104A1 (en) | 2021-06-29 | 2024-09-26 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| PE20240638A1 (es) | 2021-07-14 | 2024-03-27 | Genentech Inc | Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| CN122459678A (zh) | 2023-12-29 | 2026-07-24 | 百时美施贵宝公司 | KRAS抑制剂与Treg耗竭剂的组合疗法 |
| CN119775429B (zh) * | 2024-12-26 | 2026-08-07 | 南开大学 | 一种抗人her2/ccr4的双特异性抗体及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO2000032634A1 (en) | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
| CN1296960A (zh) * | 1999-11-22 | 2001-05-30 | 上海博容基因开发有限公司 | 一种新的多肽——人ccr4相关蛋白31和编码这种多肽的多核苷酸 |
| CN100430420C (zh) | 2001-08-31 | 2008-11-05 | 协和发酵工业株式会社 | 人cdr-移植抗体及其抗体片段 |
| US20040109847A1 (en) * | 2002-07-15 | 2004-06-10 | Lieping Chen | Treatment and prophylaxis with 4-1BB-binding agents |
| DE602004029934D1 (de) | 2003-12-04 | 2010-12-16 | Kyowa Hakko Kirin Co Ltd | Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament |
| GB0409799D0 (en) * | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| CA2588157A1 (en) | 2004-11-17 | 2006-05-26 | Board Of Regents, The University Of Texas System | Cancer immunotherapy incorporating p53 |
| WO2006088447A1 (en) * | 2005-02-15 | 2006-08-24 | Gtc Biotherapeutics, Inc. | An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof |
| US20080194596A1 (en) | 2005-06-03 | 2008-08-14 | Frizer Inc. | Therapeutic Combination Including a Selective Erbb2 Inhibitor |
| WO2009086514A1 (en) | 2007-12-28 | 2009-07-09 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| NZ729044A (en) * | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| MX361929B (es) | 2010-11-19 | 2018-12-19 | Eisai R&D Man Co Ltd Star | Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes. |
-
2015
- 2015-05-15 WO PCT/US2015/031081 patent/WO2015179236A1/en not_active Ceased
- 2015-05-15 MX MX2016015181A patent/MX2016015181A/es unknown
- 2015-05-15 RU RU2016146993A patent/RU2016146993A/ru not_active Application Discontinuation
- 2015-05-15 CA CA2949214A patent/CA2949214A1/en not_active Abandoned
- 2015-05-15 CN CN201580027437.7A patent/CN106413751A/zh active Pending
- 2015-05-15 US US15/312,515 patent/US10023649B2/en not_active Expired - Fee Related
- 2015-05-15 BR BR112016026993A patent/BR112016026993A2/pt not_active Application Discontinuation
- 2015-05-15 EP EP15727159.4A patent/EP3145956A1/en not_active Withdrawn
- 2015-05-15 AU AU2015264528A patent/AU2015264528A1/en not_active Abandoned
- 2015-05-15 KR KR1020167035347A patent/KR20170004006A/ko not_active Withdrawn
- 2015-05-15 JP JP2016568497A patent/JP2017517506A/ja active Pending
-
2016
- 2016-10-27 IL IL248540A patent/IL248540A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Suurs et al. | A review of bispecific antibodies and antibody constructs in oncology and clinical challenges | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| JP2017516775A5 (enExample) | ||
| MX2024015039A (es) | Composiciones anti-cd24 y usos de las mismas | |
| JOP20200292A1 (ar) | Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان | |
| JP2017048208A5 (enExample) | ||
| JP2017510661A5 (enExample) | ||
| BRPI0918178A8 (pt) | anticorpos monoclonais para tratamento de câncer | |
| JP2019527706A5 (enExample) | ||
| JP2015214582A5 (enExample) | ||
| JP2017505782A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| JP2015500225A5 (enExample) | ||
| JP2016510028A5 (enExample) | ||
| RU2017105425A (ru) | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины | |
| NZ724368A (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| Lin et al. | Combination treatment including targeted therapy for advanced hepatocellular carcinoma | |
| RU2016150650A (ru) | Комбинированная терапия для лечения рака | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| RU2020111366A (ru) | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения | |
| JP2016521266A5 (enExample) | ||
| JP2010209081A5 (enExample) | ||
| JP2016533366A5 (enExample) |